Radix astragali traditional Chinese medicine composition for treating pulmonary nodules and application thereof

Abstract

The invention relates to the technical field of traditional Chinese medicines, and provides an astragalus membranaceus traditional Chinese medicine composition for treating pulmonary nodules and application thereof, the traditional Chinese medicine composition is prepared from the following traditional Chinese medicines: 25-30 g of astragalus membranaceus, 20-25 g of codonopsis pilosula, 20-25 g of bighead atractylodes rhizome, 10-15 g of rhizoma atractylodis, 10-15 g of poria cocos, 6-8 g of pinellia ternate, 3-5 g of dried ginger, 6-8 g of cinnamon, 5-8 g of trichosanthes kirilowii maxim, 5-8 g of pseudo-ginseng, 3-5 g of radix bupleuri and 3-5 g of rhizoma cyperi. The traditional Chinese medicine preparation disclosed by the invention plays a synergistic role in the whole effect, has the effects of tonifying qi and lung, tonifying spleen and reducing phlegm, promoting blood circulation and removing stasis and regulating the whole body function, has an obvious treatment effect on reducing the number of pulmonary nodules and reducing the diameter of the pulmonary nodules, and obviously relieves the inflammatory response of the pulmonary nodules; meanwhile, the effects of improving the weight of mice combined with a deficiency stasis model and a lung tumor model and resisting lung tumors are achieved.

Description

Technical Field

[0001] The invention belongs to the field of Chinese medicine preparations, and specifically relates to an astragalus Chinese medicine composition for treating pulmonary nodules and its application Background Art

[0002] In current medical research, pulmonary nodules are a common clinical problem. In particular, with the widespread application of lung imaging technology, the detection rate of pulmonary nodules has increased significantly. Pulmonary nodules usually include benign nodules and malignant nodules. Benign nodules may be caused by inflammation, infection, or tuberculosis, while malignant nodules may be associated with major diseases such as lung cancer. Early diagnosis and effective intervention of pulmonary nodules are important for preventing their deterioration. However, existing Western medicine treatments are mainly surgical resection or antibiotics and anti-inflammatory drugs, which have many side effects and cannot fully regulate the body's immune function. Therefore, exploring safe and effective treatment methods has become a research hotspot.

[0003] Traditional Chinese medicine has a long history in the field of treating lung diseases, especially showing unique advantages in regulating the overall function of the human body and enhancing immunity. Astragalus membranaceus, as a classic Chinese medicinal material, is widely used in the treatment of various diseases. Modern pharmacological studies have shown that astragalus has anti-inflammatory, antioxidant, and immunomodulatory effects, can enhance the body's resistance, and promote tissue repair and regeneration. Therefore, the Chinese medicine composition based on astragalus is expected to improve lung microcirculation, inhibit inflammatory response, and reduce the formation and development of nodules through a multi-pathway and multi-target mechanism of action in the treatment of lung nodules.

[0004] In traditional Chinese medicine theory, the lungs control qi and respiration. Insufficient lung qi can easily lead to invasion by exogenous pathogens, causing lung lesions such as nodules. As a traditional Chinese medicine for invigorating qi, Astragalus can regulate the whole body by strengthening the body's resistance, eliminating pathogens, and replenishing lung qi, thereby improving lung health. In the treatment of lung nodules, the combination of Astragalus and other traditional Chinese medicines can not only enhance the self-repair ability of the immune system, but also play a therapeutic role through mechanisms such as regulating inflammatory factors and inhibiting the process of fibrosis. Therefore, the treatment method for lung nodules based on the traditional Chinese medicine composition of Astragalus is in line with the theoretical thinking of overall conditioning in traditional Chinese medicine and has broad application prospects. Summary of the invention

[0005] In order to solve the above problems, the present invention first provides an Astragalus Chinese medicine composition for treating pulmonary nodules and its application.

[0006] The invention provides an astragalus Chinese medicinal composition for treating pulmonary nodules. The Chinese medicinal composition is prepared from the following raw materials by weight: 25-30g of astragalus, 20-25g of codonopsis, 20-25g of atractylodes, 10-15g of atractylodes, 10-15g of poria, 6-8g of pinellia, 3-5g of dried ginger, 6-8g of cinnamon bark, 5-8g of trichosanthes, 5-8g of notoginseng, 3-5g of bupleurum and 3-5g of cyperus.

[0007] In some embodiments, the Chinese medicine composition is prepared from the following raw materials by weight: 30g Astragalus, 25g Codonopsis, 25g Atractylodes, 15g Atractylodes, 10g Poria, 6g Pinellia, 5g Dry Ginger, 6g Cinnamon, 8g Trichosanthes, 8g Panax Notoginseng, 5g Bupleurum, and 5g Cyperus.

[0008] In some embodiments, the Chinese medicine composition is prepared from the following raw materials by weight: 30g of Astragalus, 20g of Codonopsis, 20g of Atractylodes, 10g of Atractylodes, 15g of Poria, 8g of Pinellia, 5g of Dry Ginger, 6g of Cinnamon, 5g of Trichosanthes, 8g of Panax Notoginseng, 5g of Bupleurum, and 5g of Cyperus.

[0009] In some embodiments, the Chinese medicine composition is prepared from the following raw materials by weight: 25g Astragalus, 20g Codonopsis, 20g Atractylodes, 15g Atractylodes, 10g Poria, 8g Pinellia, 3g Dry Ginger, 6g Cinnamon, 5g Trichosanthes, 5g Panax Notoginseng, 3g Bupleurum, and 3g Cyperus.

[0010] In some embodiments, the Chinese medicine composition is prepared from the following raw materials by weight: 30g of Astragalus, 20g of Codonopsis, 25g of Atractylodes, 10g of Atractylodes, 10g of Poria, 6g of Pinellia, 5g of Dry Ginger, 8g of Cinnamon, 8g of Trichosanthes, 5g of Panax Notoginseng, 3g of Bupleurum, and 5g of Cyperus.

[0011] In some embodiments, the Chinese medicine composition is prepared from the following raw materials by weight: 25g Astragalus, 25g Codonopsis, 20g Atractylodes, 15g Atractylodes, 15g Poria, 6g Pinellia, 3g Dry Ginger, 6g Cinnamon, 8g Trichosanthes, 8g Panax Notoginseng, 3g Bupleurum, and 3g Cyperus.

[0012] In addition, the present invention also provides an application of a traditional Chinese medicine preparation in preparing a medicine for preventing and treating pulmonary nodules.

[0013] The medication mechanism of each Chinese medicine raw material of the present invention is as follows:

[0014] Main herbs: Astragalus, Codonopsis, Atractylodes

[0015] Astragalus: Astragalus is the primary medicine for invigorating qi and benefiting the lungs. It can invigorate the lungs and spleen, invigorate qi and strengthen the exterior, and enhance the body's immunity. Astragalus polysaccharides can promote bone marrow hematopoiesis, enhance immune regulation, stimulate the activity of macrophages and NK cells, enhance the body's ability to resist infection and tumors, help eliminate lung nodules and prevent their recurrence. Astragalus can resist exogenous pathogens and protect the lungs from external invasion by strengthening lung qi and strengthening the body.

[0016] Codonopsis: Codonopsis can replenish qi, strengthen the spleen and nourish the lungs, enhance the production of qi and blood in the body, improve immunity, and relieve the symptoms of dyspnea and fatigue caused by weak lung qi. Codonopsis also helps to clear moisture from the body and reduce the accumulation of phlegm and dampness by enhancing the function of spleen and stomach.

[0017] Atractylodes macrocephala: Atractylodes macrocephala can strengthen the spleen and dry out dampness. By strengthening the spleen and stomach's function of transporting and transforming water and dampness, it can effectively remove the accumulation of phlegm and dampness in the body and reduce the formation of lung nodules. In addition, Atractylodes macrocephala also has an immune-regulating effect, enhancing the body's ability to resist external pathogens.

[0018] These three herbs work together to replenish the Qi of the spleen and lungs, consolidate the positive Qi, enhance the body's ability to defend against external pathogens, and prevent the deterioration of lung nodules.

[0019] Assistant medicine: Atractylodes, Poria, Pinellia

[0020] Atractylodes: Atractylodes can dry up dampness and strengthen the spleen, effectively clearing the dampness accumulated in the body, preventing phlegm and dampness from accumulating in the lungs, and helping to reduce lung nodules caused by phlegm and dampness blocking the lungs. It also has antibacterial and anti-inflammatory effects, can reduce chronic inflammatory reactions in the lungs, and reduce the proliferation of lung nodules.

[0021] Poria: Poria strengthens the spleen and eliminates dampness, promotes diuresis and reduces swelling, can promote water and moisture metabolism in the body, and alleviate nodules caused by accumulation of damp heat in the lungs. The immunomodulatory effect of Poria helps to enhance the body's disease resistance and synergistically clear phlegm and dampness.

[0022] Pinellia: Pinellia can dry out dampness and resolve phlegm, dissipate lumps and resolve nodules, and can clear phlegm and dampness in the lungs and prevent phlegm and blood stasis from stagnating in the lungs. Pinellia has a significant anti-inflammatory effect, and by regulating the secretion of phlegm in the respiratory tract, it promotes lung patency and prevents the development of nodules.

[0023] The auxiliary drugs focus on strengthening the spleen and eliminating dampness, regulating qi and resolving phlegm, and improving lung function by removing the accumulation of phlegm and dampness, preventing lung nodules caused by phlegm and dampness.

[0024] Auxiliary drugs: Aconite, Cinnamon

[0025] Aconite: Aconite warms the yang and nourishes the kidney, restores yang and rescues adverse conditions, can replenish kidney yang deficiency, and regulate the body's overall yang level. The recovery of kidney yang plays an important role in strengthening the body, helping to improve the body's overall resistance and prevent pathogens from further invading the lungs.

[0026] Cinnamon: Cinnamon warms the yang and dredges the meridians, invigorates blood circulation and dispels cold, which can promote blood circulation, improve the blockage of qi and blood in the lungs, enhance lung microcirculation, and reduce the accumulation of phlegm and blood stasis. In addition, cinnamon has a strong anti-inflammatory effect and helps relieve chronic inflammatory reactions.

[0027] The combination of aconite and cinnamon can effectively enhance the body's yang energy by tonifying the kidney and promoting yang, dispelling cold and unblocking meridians, strengthening the body, further regulating qi and blood in the lungs, and reducing the development of lung nodules.

[0028] Auxiliary drugs: Trichosanthes, Panax notoginseng

[0029] Trichosanthes: Trichosanthes can clear away heat and resolve phlegm, dissipate nodules and relieve chest tightness. It can effectively dilute phlegm and remove phlegm and dampness accumulation. Its nodule-dispersing effect can help dissipate nodules and prevent them from growing larger. In addition, Trichosanthes can also improve the patency of the respiratory tract and relieve lung pressure.

[0030] Panax notoginseng: Panax notoginseng can promote blood circulation, remove blood stasis, reduce swelling and relieve pain, effectively improve lung microcirculation, reduce the accumulation of blood stasis in the lungs, promote the discharge of blood stasis, and prevent further deterioration of lung nodules. Panax notoginseng's anti-inflammatory and anti-tumor effects help inhibit the growth and spread of nodules.

[0031] The combination of Trichosanthes kirilowii and Panax notoginseng can promote the dissipation of nodules and improve lung ventilation and blood flow by resolving phlegm and dispersing nodules, and activating blood circulation and unblocking meridians.

[0032] Adjuvant drugs: Bupleurum, Cyperus

[0033] Bupleurum: Bupleurum can relieve liver qi stagnation, raise yang qi, regulate liver qi stagnation, and prevent lung nodules caused by qi blockage. It helps relieve lung discomfort and prevent nodule hyperplasia by regulating liver function and unblocking qi.

[0034] Cyperus rotundus: Cyperus rotundus can regulate qi and relieve depression, regulate menstruation and relieve pain, regulate qi stagnation symptoms, promote qi and blood circulation, and avoid phlegm and dampness accumulation caused by qi stagnation in the lungs. Cyperus rotundus can also help enhance the body's overall immune function and improve disease resistance.

[0035] Bupleurum and Cyperus rotundus work together to regulate liver qi, soothe the liver and regulate qi, solve the problem of lung nodules caused by qi stagnation, and further improve the condition of poor lung qi movement.

[0036] Compared with the existing technology for treating lung nodules, the beneficial effects of the present invention are mainly reflected in: the main medicine nourishes the lungs and replenishes qi, strengthens the spleen and consolidates the foundation, and enhances the body's disease resistance; the minister medicine nourishes the spleen and eliminates dampness, and clears phlegm and dampness accumulation; the adjuvant medicine warms the yang and dredges the collaterals, dispels cold and eliminates phlegm, further resolves phlegm and resolves nodules, activates blood circulation and dredges the collaterals, and at the same time regulates liver qi and dredges qi. The overall effect is synergistically exerted to achieve the effects of nourishing qi and benefiting the lungs, strengthening the spleen and resolving phlegm, activating blood circulation and dispersing nodules, and regulating the function of the whole body, effectively eliminating and preventing the occurrence and development of lung nodules.

[0037] In addition, the combined use of the above-mentioned Chinese medicinal materials in the present invention has an obvious therapeutic effect on reducing the number of lung nodules and reducing the diameter of lung nodules, and can significantly reduce the inflammatory response of lung nodules. At the same time, it has the effect of improving the body weight of mice in the deficiency and stasis model combined with the lung tumor model and anti-tumor effect, thereby achieving the purpose of delaying or treating lung nodules or lung tumors. DETAILED DESCRIPTION

[0038] In order to make the technical problems to be solved, technical solutions and advantages of the present invention more clear, they are described in detail below in conjunction with specific embodiments.

[0039] Example 1

[0040] A Chinese medicine composition 1 for treating pulmonary nodules is prepared from the following raw materials by weight:

[0041] Astragalus 30g, Codonopsis pilosula 25g, Atractylodes macrocephala 25g, Atractylodes lancea 15g, Poria 10g, Pinellia 6g, Dry ginger 5g, Cinnamon bark 6g, Trichosanthes kirilowii 8g, Panax notoginseng 8g, Bupleurum 5g, Cyperus rotundus 5g.

[0042] Example 2

[0043] A Chinese medicine composition 2 for treating pulmonary nodules is prepared from the following raw materials by weight:

[0044] Astragalus 30g, Codonopsis pilosula 20g, Atractylodes macrocephala 20g, Atractylodes lancea 10g, Poria 15g, Pinellia 8g, Dry ginger 5g, Cinnamon bark 6g, Trichosanthes kirilowii 5g, Panax notoginseng 8g, Bupleurum 5g, Cyperus rotundus 5g.

[0045] Example 3

[0046] A Chinese medicine composition 3 for treating pulmonary nodules is prepared from the following raw materials by weight:

[0047] Astragalus 25g, Codonopsis pilosula 20g, Atractylodes macrocephala 20g, Atractylodes lancea 15g, Poria 10g, Pinellia 8g, Dry ginger 3g, Cinnamon bark 6g, Trichosanthes kirilowii 5g, Panax notoginseng 5g, Bupleurum 3g, Cyperus rotundus 3g.

[0048] Example 4

[0049] A Chinese medicine composition 4 for treating pulmonary nodules is prepared from the following raw materials by weight:

[0050] Astragalus 30g, Codonopsis pilosula 20g, Atractylodes macrocephala 25g, Atractylodes lancea 10g, Poria 10g, Pinellia 6g, Dry ginger 5g, Cinnamon bark 8g, Trichosanthes kirilowii 8g, Panax notoginseng 5g, Bupleurum 3g, Cyperus rotundus 5g.

[0051] Example 5

[0052] A Chinese medicine composition 5 for treating pulmonary nodules is prepared from the following raw materials by weight:

[0053] Astragalus 25g, Codonopsis pilosula 25g, Atractylodes macrocephala 20g, Atractylodes lancea 15g, Poria 15g, Pinellia 6g, Dry ginger 3g, Cinnamon bark 6g, Trichosanthes kirilowii 8g, Panax notoginseng 8g, Bupleurum 3g, Cyperus rotundus 3g.

[0054] Example 6

[0055] A method for preparing a Chinese medicine composition for treating pulmonary nodules comprises the following steps: preparing raw medicinal materials according to the formula of any one of Examples 1-5, weighing all the processed, dried and pulverized raw medicinal materials according to the weight ratio described in any one of Examples 1-5, fully mixing the medicinal materials to ensure that the medicinal materials are evenly distributed, using a Chinese medicine decoction machine or a double-layer stainless steel cooker, adding water (about 1200-1500 ml) according to 8-10 times the total weight of the medicinal materials, soaking the medicinal materials for 30 minutes to allow them to fully absorb water, decocting for the first time: boiling over high heat, then turning to low heat, maintaining a slight boil, decocting for 30-40 minutes, and collecting the medicinal liquid; decocting for the second time: adding water to 70-80% of the volume of the original liquid, continuing to boil for 30 minutes, collecting the medicinal liquid, filtering the medicinal liquid with gauze or a filter after each decoction to remove the medicinal residue; combining the medicinal liquids after the two decoctions, placing them in a low-temperature concentration device, controlling the temperature at 60-80°C, and concentrating them to about 100-300 ml of medicinal liquid to ensure the concentration of effective ingredients.

[0056] Example 7 Pharmacological Animal Experiment

[0057] C57BL / 6 mice were selected, regardless of sex, with a weight range of 180g-220g. According to the experimental requirements, 7 groups were set up, namely, Chinese medicine composition 1, Chinese medicine composition 2, Chinese medicine composition 3, Chinese medicine composition 4, Chinese medicine composition 5, control group, and model group; each group had 12 animals. The mice were adapted to the environment and raised for one week after arriving at the laboratory. The mice were fed with standard experimental animal feed under conventional feeding conditions and were free to eat and drink water. The establishment of the pulmonary nodule model was induced by using benzopyrene (B(a)P) compounds to induce the formation of pulmonary nodules in mice. B(a)P (50 mg / kg) was used and administered by intraperitoneal injection for 4 consecutive weeks to induce pulmonary nodules. Chinese medicine composition 1, Chinese medicine composition 2, Chinese medicine composition 3, Chinese medicine composition 4, Chinese medicine composition 5, and the model group were given corresponding treatments after the model was established.

[0058] The following treatments were performed on the experimental groups:

[0059] Chinese medicine composition group 1 (CMM1): After the pulmonary nodule model was established, the mice were given Chinese medicine composition 1 of Astragalus membranaceus at a dose of 200 mg / kg for 28 consecutive days.

[0060] Chinese medicine composition group 2 (CMM2): After the pulmonary nodule model was established, the mice were given Chinese medicine composition 2 of Astragalus membranaceus at a dose of 200 mg / kg for 28 consecutive days.

[0061] Chinese medicine composition 3 group (CMM3): After the pulmonary nodule model was established, the mice were given Chinese medicine composition 3 of Astragalus membranaceus at a dose of 200 mg / kg for 28 consecutive days.

[0062] Chinese medicine composition group 4 (CMM4): After the pulmonary nodule model was established, the mice were given Chinese medicine composition 4 of Astragalus membranaceus at a dose of 200 mg / kg for 28 consecutive days.

[0063] Chinese medicine composition 5 group (CMM5): After the pulmonary nodule model was established, the mice were given Chinese medicine composition 5 of Astragalus membranaceus at a dose of 200 mg / kg for 28 consecutive days.

[0064] Normal control group (NC): No treatment was given, and 200 mg / kg normal saline was administered for 28 consecutive days.

[0065] Model group (MC): After induction of pulmonary nodule formation, no drug treatment was given, but 200 mg / kg normal saline was given for 28 consecutive days.

[0066] Positive control group (PC): After inducing lung nodule formation, 0.1 mg / kg dexamethasone was given for 28 consecutive days.

[0067] Detection of changes in the diameter of lung nodules in model mice: Computed tomography (CT) is a commonly used non-invasive imaging technique that can clearly display lung nodules and monitor changes in nodule size in multiple scans. A high-resolution small animal CT scanner (Skyscan 1176); after the induction of lung nodules, regular scans were performed according to experimental needs, such as once every 1-2 weeks, to observe the changes in nodules; before scanning, the mice were anesthetized with isoflurane or pentobarbital to ensure their stability during the scanning process; the scanning parameters were voltage: 50-70 kV, current: 100-200 μA, and the pixel size was suitable for the resolution of mouse lung nodule detection to reach 20-50 μm; three-dimensional reconstruction was performed using the CT scanner supporting software, and in the reconstructed three-dimensional image, the lung nodules were manually or automatically located, and the maximum diameter of the nodules was measured using ImageJ software, and the nodule diameter of each scan was recorded, and the maximum diameter of the nodules before drug administration (day 0) and after drug administration (day 28) were compared, and the statistical software SPSS was used for inter-group comparison to analyze the effect of therapeutic drugs on the change of nodule diameter, as shown in Table 1.

[0068] Table 1 Comparison of the maximum diameter of lung nodules before and after administration mm

[0069] Group Before giving the Chinese medicine composition After giving the Chinese medicine composition Chinese medicine composition 1 (CMM1) <![CDATA[5.34±1.97 d ]]> <![CDATA[2.75±1.24 a ]]> Chinese medicine combination 2 (CMM2) <![CDATA[5.13±0.57 c ]]> <![CDATA[2.95±0.73 b ]]> Chinese medicine combination group 3 (CMM3) <![CDATA[5.54±1.49 d ]]> <![CDATA[2.68±0.27 b ]]> Chinese medicine combination 4 (CMM4) <![CDATA[5.61±0.45 c ]]> <![CDATA[2.80±1.05 a ]]> Chinese medicine combination 5 (CMM5) <![CDATA[5.42±1.74 c ]]> <![CDATA[2.32±1.35 a ]]> Group Before giving saline After giving saline Normal control group (NC) 0.09±0.007 0.08±0.004 Model group (MC) <![CDATA[5.23±1.23 c ]]> <![CDATA[5.68±1.17 c ]]> Group Before giving dexamethasone After dexamethasone Positive control group (PC) <![CDATA[5.68±1.07 d ]]> <![CDATA[3.56±1.05 a ]]>

[0070] Note: Compared with before treatment, a P<0.05, b P<0.01; compared with the normal control group,c P<0.05, d P<0.01.

[0071] The results in Table 1 show that the diameter of lung nodules in the model group and each group before administration of the Chinese medicine composition was significantly larger than that in the normal control group, indicating that the modeling of each group was successful; and the diameter of lung nodules in the Chinese medicine composition group 1 to the Chinese medicine composition group 5 was significantly reduced after treatment with the Chinese medicine composition (P<0.05).

[0072] Detection of changes in the number of lung nodules in model mice: Before administration (day 0) and after administration (day 28), CT scans were performed on each group of mice to detect the number of lung nodules. The lung images of each mouse were processed using CT analysis software to record changes in the number of lung nodules, with special attention paid to whether the number of nodules was significantly reduced.

[0073] Table 2 Comparison of the number of pulmonary nodules before and after administration (number)

[0074] Group Before giving the Chinese medicine composition After giving the Chinese medicine composition Chinese medicine composition 1 (CMM1) 15 <![CDATA[7 a ]]> Chinese medicine combination 2 (CMM2) 17 <![CDATA[6 b ]]> Chinese medicine combination group 3 (CMM3) 18 <![CDATA[5 b ]]> Chinese medicine combination 4 (CMM4) 20 <![CDATA[8 a ]]> Chinese medicine combination 5 (CMM5) 16 <![CDATA[9 a ]]> Group Before giving saline After giving saline Normal control group (NC) 0 0 Model group (MC) 18 18 Group Before giving dexamethasone After dexamethasone Positive control group (PC) 19 <![CDATA[9 b ]]>

[0075] Note: Compared with before treatment, a P<0.05, b P<0.01; compared with the normal control group, c P<0.05, d P<0.01.

[0076] The results in Table 2 show that the number of lung nodules in the model group and the groups treated with the Chinese medicine composition was significantly increased compared with the normal control group, indicating that the modeling of each group was successful; and the number of lung nodules in the Chinese medicine composition group 1 to the Chinese medicine composition group 5 was significantly reduced after treatment with the Chinese medicine composition (P<0.05).

[0077] Detection of cytokines TNF-α, IL-6, and TGF-β: After 28 days, part of the lung tissue was taken from each experimental group, and the lung tissue homogenate was prepared with PBS. After centrifugation at 10000g for 10 minutes, the supernatant was taken; the concentration of TNF-α, IL-6, and TGF-β in the mouse lung tissue was detected by enzyme-linked immunosorbent assay (ELISA). The ELISA kit was operated according to the manufacturer's instructions. The specific detection steps are as follows: add standard products, test samples, and blank controls to the enzyme-labeled plate, and set up duplicate wells for each group; add cytokine-specific antibodies and incubate for 2 hours at 37°C. After washing the plate, add enzyme conjugates and incubate for 1 hour at 37°C. After washing the plate again, add substrate solution and incubate at room temperature for 15-30 minutes. After terminating the reaction, measure the absorbance at a wavelength of 450nm and calculate the cytokine concentration, as shown in Table 3.

[0078] Table 3 Detection results of cytokines TNF-α, IL-6, and TGF-β

[0079]

[0080]

[0081] Note: Compared with the model group, a P<0.05, b P<0.01; compared with the normal control group, c P<0.05, d P<0.05.

[0082] The results in Table 3 show that compared with the normal control group, the expression levels of cytokines TNF-α, IL-6, and TGF-β in the model group were significantly increased, indicating that the modeling was successful; the expression levels of cytokines TNF-α, IL-6, and TGF-β in the rats in the Chinese medicine composition group 1 to the Chinese medicine composition group 5 were significantly decreased compared with the model group (P < 0.05); this shows that Chinese medicine compositions 1-5 have different degrees of anti-inflammatory effects, reduce the inflammatory response of lung nodules, and thus treat lung nodules.

[0083] Construction of lung tumor rat model by combining deficiency and stasis model with Lewis lung cancer cell inoculation:

[0084] Chronic fatigue method (Qi deficiency model): SPF Wistar rats of either sex were selected, with a weight range of 180g-220g. The rats were subjected to physical fatigue training for several consecutive days, and fatigue was induced by swimming or running. The rats were placed in water for swimming every day, and the water temperature was maintained at 25±2℃ and the depth was 5cm. The rats were fished out after swimming until they were exhausted (usually about 10 minutes). Training was performed once a day for 2-4 weeks until the rats were physically weak and had obvious symptoms of Qi deficiency. The rats showed symptoms of Qi deficiency such as weight loss, reduced activity, and dull hair.

[0085] Cold stress method (cold coagulation and blood stasis model): SPF Wistar rats treated with chronic fatigue method were placed in a low temperature environment (4°C) for 30 minutes each time, once a day, for 2-4 weeks. Low temperature stimulation can cause cold evil to invade the body, thus forming a state of deficiency cold and blood stasis. The mice lost weight, had reduced activity, and had cold limbs, indicating cold coagulation and blood stasis.

[0086] The chronic fatigue method and the cold stress method were used to construct the asthenia stasis model rats, and then Lewis lung cancer cells were inoculated in the asthenia stasis model rats to simulate the occurrence of lung cancer. The specific steps are as follows: Lewis lung cancer cells were cultured in RPMI-1640 medium containing 10% fetal bovine serum to the logarithmic growth phase, and the cells grew well. The cells were digested and centrifuged, and the cells were resuspended in sterile PBS and the cell concentration was adjusted to 1×10 6 -1×10 7The rats with deficiency and stasis model were anesthetized (sodium pentobarbital can be used, with a dose of 50 mg / kg intraperitoneal injection). Under sterile conditions, 1×10 Lewis lung cancer cell suspension was taken. 6 -1×10 7 cells / mL, injected through the tail vein, with an injection volume of 100μL. Within 7-14 days after inoculation, rats will form tumors in their lungs. After Lewis lung cancer cells are inoculated, multiple nodules or tumors gradually form in the lungs of rats. Combined with the deficiency and stasis model, the growth rate of nodules is accelerated, which may show more serious lung lesions, and is suitable for observing tumor growth and experimental treatment effects.

[0087] The asthenia and stasis model combined with the lung tumor rat model were divided into groups and treated as follows:

[0088] Chinese medicine group 1 (CM1): After the deficiency-stasis combined with lung tumor model was established, the Chinese medicine composition 1 of Astragalus membranaceus was administered at a dose of 200 mg / kg for 28 consecutive days.

[0089] Chinese medicine group 2 (CM2): After the deficiency-stasis combined with lung tumor model was established, the Chinese medicine composition 2 of Astragalus membranaceus was administered at a dose of 200 mg / kg for 28 consecutive days.

[0090] Chinese medicine group 3 (CM3): After the deficiency-stasis combined with lung tumor model was established, the Chinese medicine composition 3 of Astragalus membranaceus was administered at a dose of 200 mg / kg for 28 consecutive days.

[0091] Chinese medicine group 4 (CM4): After the deficiency-stasis combined with lung tumor model was established, the Chinese medicine composition 4 of Astragalus membranaceus was administered at a dose of 200 mg / kg for 28 consecutive days.

[0092] Chinese medicine group 5 (CM5): After the deficiency-stasis combined with lung nodule model was established, the Chinese medicine composition 5 of Astragalus membranaceus was administered at a dose of 200 mg / kg for 28 consecutive days.

[0093] Blank group (CN): No treatment was performed, and 200 mg / kg normal saline was administered for 28 consecutive days.

[0094] Model group (MC): After the deficiency-stasis combined with lung tumor model was established, no drug treatment was given, but 200 mg / kg normal saline was given for 28 consecutive days.

[0095] Table 4 Body weight changes of rats in each group ( g)

[0096] Group Before administration (Day 0) After administration (Day 28) Chinese Medicine Group 1 (CM1) <![CDATA[21.35±1.56 c ]]> <![CDATA[23.44±2.17 a ]]> Chinese Medicine Group 2 (CM2) <![CDATA[20.34±2.83 d ]]> <![CDATA[23.19±1.39 b ]]> Chinese Medicine Group 3 (CM3) <![CDATA[21.96±1.94 c ]]> <![CDATA[24.47±2.52 b ]]> Chinese Medicine Group 4 (CM4) <![CDATA[21.56±2.49 d ]]> <![CDATA[24.75±1.39 a ]]> Chinese Medicine Group 5 (CM5) <![CDATA[21.34±1.92 d ]]> <![CDATA[23.29±2.03 a ]]> Blank group (CN) 25.16±2.52 25.67±1.24 Model group (MC) <![CDATA[21.34±2.12 c ]]> <![CDATA[21.12±2.71 c ]]>

[0097] Note: Compared with the model group, a P<0.05, b P<0.01; compared with the blank group, cP<0.05, d P<0.05.

[0098] The results in Table 4 show that before administration (day 0), the body weights of TCM group 1 to TCM group 5 and the model group were lower than those of the blank group (P < 0.05), indicating that modeling would affect the body weight of rats. After drug intervention (day 28), the body weights of TCM group 1 to TCM group 5 and the blank group were higher than those of the model group (P < 0.05). The results indicate that the Chinese medicine composition of the present invention has the effect of improving the body weight of rats.

[0099] Table 5 Changes in tumor mass of rats in each group ( g)

[0100] Group Tumor mass Chinese Medicine Group 1 (CM1) <![CDATA[2.15±0.35 a ]]> Chinese Medicine Group 2 (CM2) <![CDATA[2.04±0.28 b <!-- 7 -->]]> Chinese Medicine Group 3 (CM3) <![CDATA[2.15±0.21 b ]]> Chinese Medicine Group 4 (CM4) <![CDATA[2.25±0.32 a ]]> Chinese Medicine Group 5 (CM5) <![CDATA[2.07±0.23 b ]]> Model group (MC) 4.32±0.25

[0101] Note: Compared with the model group, a P<0.05, b P<0.01.

[0102] The results in Table 4 show that compared with the model group, the tumor weight of rats in Chinese medicine group 1 to Chinese medicine group 5 was significantly lower than that in the model group (P < 0.05), and the tumor weight of Chinese medicine group 1 and Chinese medicine group 5 was even lower (P < 0.01). The results indicate that the Chinese medicine composition of the present invention also has a certain inhibitory effect on rat lung cancer tissue.

[0103] The above is a preferred embodiment of the present invention. It should be pointed out that for ordinary technicians in this technical field, several improvements and modifications can be made without departing from the principles of the present invention. These improvements and modifications should also be regarded as the scope of protection of the present invention.

Claims

1. An Astragalus Chinese medicine composition for treating pulmonary nodules, characterized in that: The Chinese medicine composition is prepared from the following raw materials by weight: 25-30g of Astragalus, 20-25g of Codonopsis, 20-25g of Atractylodes, 10-15g of Atractylodes, 10-15g of Poria, 6-8g of Pinellia, 3-5g of Dry Ginger, 6-8g of Cinnamon, 5-8g of Trichosanthes, 5-8g of Panax Notoginseng, 3-5g of Bupleurum, and 3-5g of Cyperus.

2. The Astragalus Chinese medicine composition according to claim 1, characterized in that The Chinese medicine composition is prepared from the following raw materials by weight: 30g of Astragalus, 25g of Codonopsis, 25g of Atractylodes, 15g of Atractylodes, 10g of Poria, 6g of Pinellia, 5g of Dry Ginger, 6g of Cinnamon, 8g of Trichosanthes, 8g of Panax Notoginseng, 5g of Bupleurum, and 5g of Cyperus.

3. The Astragalus Chinese medicine composition according to claim 1, characterized in that: The Chinese medicine composition is prepared from the following raw materials by weight: 30g of Astragalus, 20g of Codonopsis, 20g of Atractylodes, 10g of Atractylodes, 15g of Poria, 8g of Pinellia, 5g of Dry Ginger, 6g of Cinnamon, 5g of Trichosanthes, 8g of Panax Notoginseng, 5g of Bupleurum, and 5g of Cyperus.

4. The Astragalus Chinese medicine composition according to claim 1, characterized in that: The Chinese medicine composition is prepared from the following raw materials by weight: 25g of Astragalus, 20g of Codonopsis, 20g of Atractylodes, 15g of Atractylodes, 10g of Poria, 8g of Pinellia, 3g of Dry Ginger, 6g of Cinnamon, 5g of Trichosanthes, 5g of Panax Notoginseng, 3g of Bupleurum, and 3g of Cyperus.

5. The Astragalus Chinese medicine composition according to claim 1, characterized in that: The Chinese medicine composition is prepared from the following raw materials by weight: 30g of Astragalus, 20g of Codonopsis, 25g of Atractylodes, 10g of Atractylodes, 10g of Poria, 6g of Pinellia, 5g of Dry Ginger, 8g of Cinnamon, 8g of Trichosanthes, 5g of Panax Notoginseng, 3g of Bupleurum, and 5g of Cyperus.

6. The Astragalus Chinese medicine composition according to claim 1, characterized in that: The Chinese medicine composition is prepared from the following raw materials by weight: 25g of Astragalus, 25g of Codonopsis, 20g of Atractylodes, 15g of Atractylodes, 15g of Poria, 6g of Pinellia, 3g of Dry Ginger, 6g of Cinnamon, 8g of Trichosanthes, 8g of Panax Notoginseng, 3g of Bupleurum, and 3g of Cyperus.

7. Use of the Chinese medicine composition according to any one of claims 1 to 6 in the preparation of a medicine for treating pulmonary nodules.

Images